Tomo T.a· Takei M.b· Matsuyama M.c· Matsuyama I.c· Matsuyama K.d

Author affiliations

aClinical Engineering Research Center, Oita University Hospital, Oita, Japan
bSuwa No Mori Hospital, Koshinkai Medical Corporation, Oita, Japan
cOita Internal Medicine Clinic, Kenjinkai Healthcare Corporation, Oita, Japan
dMatsuyama Clinic Oita Nephro Internal Medicine Department, Seiikai Medical Corporation, Oita, Japan

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: March 30, 2022
Accepted: February 14, 2023
Published online: March 30, 2023

Number of Print Pages: 9
Number of Figures: 2
Number of Tables: 3

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Abstract

Introduction: In this study, we examined the effect of switching dialysis membranes on the response to influenza virus vaccination in HD patients. Methods: This study consisted of two phases. In phase 1, antibody titers were measured and compared between HD patients and healthy volunteers (HVs) before and after vaccination against influenza virus. Using antibody titers 4 weeks after vaccination, HD patients and HVs were classified according to seroconversion (i.e., antibody titers against all four strains were >20-fold) or non-seroconversion (i.e., antibody titer against at least one strain was <20-fold). In the phase 2, we examined whether the change in the dialysis membrane from a polysulfone (PS) to a polymethyl methacrylate (PMMA) membrane affected the response to vaccination in HD patients without seroconversion in response to the vaccine the previous year. Patients with seroconversion and non-seroconversion were classified as responders and nonresponders, respectively. Additionally, we compared clinical data. Results: In the phase 1, 110 HD patients and 80 HVs were enrolled, and their seroconversion rates were 58.6% and 72.5%, respectively. In the phase 2, 20 HD patients without seroconversion in response to the vaccine the previous year were enrolled, and the dialyzer membrane was changed to PMMA 5 months before annual vaccination. After annual vaccination, 5 and 15 HD patients were categorized as responders and nonresponders, respectively. In the responders, β2-microglobulin, white blood cell counts, platelet counts, and serum albumin levels (Alb) were all higher than in the nonresponders. Conclusion: The responsiveness to vaccination against influenza virus was lower in HD patients compared with HVs. Changing the dialysis membrane from PS to PMMA appeared to affect the response to vaccination in HD patients.

© 2023 S. Karger AG, Basel

References Sharif MR, Chitsazian Z, Moosavian M, Raygan F, Nikoueinejad H, Sharif AR, et al. Immune disorders in hemodialysis patients. Iran J Kidney Dis. 2015 Mar;9(2):84–96. Espi M, Koppe L, Fouque D, Thaunat O. Chronic kidney disease-associated immune dysfunctions: impact of protein-bound uremic retention solutes on immune cells. Toxins. 2020 May 6;12(5):300. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The advisory committee on immunization practices and the American academy of pediatrics. Semin Dial. 2000 Mar-Apr;13(2):101–7. Song JY, Cheong HJ, Ha SH, Kee SY, Jeong HW, Kim WJ. Active influenza immunization in hemodialysis patients: comparison between single-dose and booster vaccination. Am J Nephrol. 2006;26(2):206–11. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020 Jul;98(1):20–6. Moore LR, Al-Jaddou N, Wodeyar H, Sharma A, Schulz M, Rao A, et al. SARS-CoV-2 in dialysis patients and the impact of vaccination. BMC Nephrol. 2022 Sep 21;23(1):317. Sakai Y. Polymethylmethacrylate membrane with a series of serendipity. Contrib Nephrol. 2011;173:137–47, Aucella F, Vigilante M, Gesuete A, Maruccio G, Specchio A, Gesualdo L. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role? Nephrol Dial Transpl. 2007 Jul;22(Suppl 5):v8–12. Lin HH, Liu YL, Liu JH, Chou CY, Yang YF, Kuo HL, et al. Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney. Artif Organs. 2008 Jun;32(6):468–72. Masakane I. High-quality dialysis: a lesson from the Japanese experience: effects of membrane material on nutritional status and dialysis-related symptoms. NDT Plus. 2010 May;3(Suppl 1):i28–i35. Contin-Bordes C, Lacraz A, de Précigout V. Potential role of the soluble form of CD40 in deficient immunological function of dialysis patients: new findings of its amelioration using polymethylmethacrylate (PMMA) membrane. NDT Plus. 2010 May;3(Suppl 1):i20–7. Duranti E, Duranti D. Polymethylmethacrylate strengthens antibody response in hemodialysis patients not responding to hepatitis B vaccine: preliminary data. Minerva Med. 2011 Dec;102(6):469–74. Peraldi MN, Berrou J, Métivier F, Toubert A. Natural killer cell dysfunction in uremia: the role of oxidative stress and the effects of dialysis. Blood Purif. 2013;35(Suppl 2):14–9. Abe M, Hamano T, Wada A, Nakai S, Masakane I. High-performance membrane dialyzers and mortality in hemodialysis patients: a 2-year cohort study from the annual survey of the Japanese renal data registry. Am J Nephrol. 2017;46(1):82–92. Abe M, Hamano T, Wada A, Nakai S, Masakane I; Renal Data Registry Committee, Japanese Society for Dialysis Therapy. Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: results from the annual survey of the Japanese nationwide dialysis registry. PLoS One. 2017 Sep 14;12(9):e0184424. Duranti E, Imperiali P, Gabbrilelli C, Conti P, Lombardi M, Sidoti A. Hemodialysis with polymethylmethacrylate restores the response to hepatitis B vaccination in chronic dialysis patients: hypothesized mechanism of action. Arch Ren Dis Manag. 2016 ;2(1):001–4, Chang YT, Wang JR, Lin MT, Wu CJ, Tsai MS, Wen-Chi CL, et al. Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients: an 18-week, open-label trial. Sci Rep. 2016;6:20725. Liao Z, Xu X, Liang Y, Xiong Y, Chen R, Ni J. Effect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients: a systematic literature review and meta-analysis. Hum Vaccin Immunother. 2016 Nov;12(11):2909–15. Miskulin DC, Weiner DE, Tighiouart H, Lacson EK Jr, Meyer KB, Dad T, et al. High-dose seasonal influenza vaccine in patients undergoing dialysis. Clin J Am Soc Nephrol. 2018 Nov 7;13(11):1703–11. Butler AM, Layton JB, Dharnidharka VR, Sahrmann JM, Seamans MJ, Weber DJ, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccine among patients receiving maintenance hemodialysis. Am J Kidney Dis. 2020 Jan;75(1):72–83. Nongnuch A, Ngampongpan W, Srichatrapimuk S, Wongsa A, Thongpraphai S, Boonarkart C, et al. Immune response to influenza vaccination in ESRD patients undergoing hemodialysis vs. hemodiafiltration. PLoS One. 2020 Feb 3;15(2):e0227719, de Précigout V, Germain C, Benard A, Lacraz A, Chauveau P, Deprele C, et al. No improvement of hepatitis B vaccination response in patients dialysed with a polymethylmethacrylate membrane compared to high-flux polysulfone: results of the HEPADIAL Study. Blood Purif. 2020;49(3):265–71. Ghamar-Chehreh ME, Agah S, Khedmat H, Aghaei A, Alavian SM. Serum albumin level as an indicator of response to Hepatitis B vaccination in dialysis patients: a systematic review and meta-analysis. Caspian J Intern Med. 2017 Fall;8(4):250–7. Trzeciak-Ryczek A, Tokarz-Deptuła B, Deptuła W. Platelets-an important element of the immune system. Pol J Vet Sci. 2013;16(2):407–13. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood. 2014 May 1;123(18):2759–67. Iannacone M. Platelet-mediated modulation of adaptive immunity. Semin Immunol. 2016 Dec;28(6):555–60. Min R, Li Z, Epstein J, Barlogie B, Yi Q. Beta(2)-microglobulin as a negative growth regulator of myeloma cells. Br J Haematol. 2002 Aug;118(2):495–505. Article / Publication Details

First-Page Preview

Received: March 30, 2022
Accepted: February 14, 2023
Published online: March 30, 2023

Number of Print Pages: 9
Number of Figures: 2
Number of Tables: 3

ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)

For additional information: https://www.karger.com/BPU

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.